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Abstract 
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyper-
glycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight 
loss, mainly due to reduced fat volume. We investigated the effects of empagliflozin (selective SGLT2 inhibitor) and 
linagliptin (DPP-4 inhibitor) on steatohepatitis and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH) 
with diabetes.
Methods: A novel NASH model was generated by administration of streptozotocin to C57BL/6J mice at 2 days 
old, with a high-fat diet from 4 weeks. NASH mice aged 6 weeks were divided into four groups of 6 animals: vehicle, 
linagliptin (10 mg/kg), empagliflozin (10 mg/kg), and linagliptin + empagliflozin. The histological non-alcoholic fatty 
liver disease activity score was significantly lower in the empagliflozin and linagliptin + empagliflozin groups than 
in the vehicle or linagliptin groups. Hepatic expression of inflammatory genes (tumor necrosis factor-α, interleukin-6, 
and monocyte chemoattractant protein-1) was decreased in the empagliflozin and linagliptin + empagliflozin groups 
compared with the vehicle group. The collagen deposition with Sirius red staining was significantly reduced in the 
linagliptin + empagliflozin group compared with the linagliptin or the empagliflozin group. Immunohistochemistry 
showed that expression of α-smooth muscle actin, a marker of myofibroblasts (fibrosis), was reduced in the linaglip-
tin + empagliflozin group compared with the vehicle group, as was expression of type 1 and 3 collagen mRNA. Lina-
gliptin + empagliflozin decreased expression of mRNAs for genes related to fatty acid synthesis, but did not increase 
mRNAs for β-oxidation-related genes.
Conclusions: While empagliflozin alone attenuates development of NASH showing anti-steatotic and anti-inflam-
matory effects, combined administration of empagliflozin and linagliptin can synergistically ameliorates NASH with 
stronger anti-fibrotic effects.
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Background
Non-alcoholic fatty liver disease (NAFLD) is now a 
common disease and has become a serious public 
health problem worldwide [1]. Up to 30  % of patients 
with NAFLD progress to non-alcoholic steatohepatitis 
(NASH), which is characterized by hepatocellular lipid 
accumulation (steatosis) along with lobular inflamma-
tion, hepatocellular ballooning, and fibrosis [2]. NASH is 
associated with an increased risk of cirrhosis and hepato-
cellular carcinoma (HCC) [3]. It is also closely associated 
with metabolic syndrome and type 2 diabetes, suggesting 
that NASH is the hepatic manifestation of insulin resist-
ance and type 2 diabetes [4]. Thus, establishment of phar-
macological treatment for NASH may be a useful strategy 
to prevent liver cirrhosis and HCC.
A recent study demonstrated that the DPP-4 inhibitor 
linagliptin alleviates hepatic steatosis and inflammation 
in a new murine model of NASH with a diabetic back-
ground independently of its glucose-lowering effect [5]. It 
was also reported that sitagliptin, another DPP-4 inhibi-
tor, improves histological changes of NAFLD in mice that 
have dietary obesity with or without diabetes [6, 7].
Sodium-glucose co-transporter-2 (SGLT2) inhibi-
tors are a new class of oral antidiabetic drugs, which 
act to reduce hyperglycemia by promoting urinary glu-
cose excretion independently of the secretion or action 
of insulin [8]. Empagliflozin is a highly selective SGLT2 
inhibitor that improves glycemic control in patients with 
T2DM as monotherapy or when added to metformin, 
sulfonylurea, or insulin [9]. Moderate weight loss has 
been a consistent finding in clinical studies of this drug 
[10]. In diabetic patients, most of the weight loss due to 
treatment with dapagliflozin was accounted for by fat 
loss, with significant reductions versus placebo in the vol-
ume of both abdominal visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT) [11]. In a preclini-
cal model of obesity, empagliflozin triggered weight loss 
associated with reduction of body fat that was probably 
secondary to calorie wasting in the urine [12].
Based on these reports, we hypothesized that empa-
gliflozin could prevent the development of NASH by 
acting on hepatic lipid metabolism independently of its 
glucose-lowering effect and the combination of linaglip-
tin and empagliflozin could improve synergistically. To 
date, only five studies have examined impacts of SGLT2 
inhibitors alone on development of NAFLD and/or 
NASH in rodent models [13–16]. Although four studies 
used ipragliflozin and one study used luseogliflozin, all 
studies demonstrated that SGLT2 inhibitors attenuated 
development of NAFLD or NASH [13–16]. However, no 
studies have examined the effect of empagliflozin or the 
combination of DPP-4 inhibitors and SGLT2 inhibitors 
on the development of NASH in the presence of diabetes. 
Therefore, we investigated the effect of empagliflozin and 
that of linagliptin, a DPP-4 inhibitor, on steatohepatitis 
and fibrosis in a new mouse model of NASH with a dia-
betic background, which was generated by administra-
tion of streptozotocin (STZ) to C57BL/6J mice at 2 days 
old combined with a high-fat diet from the age of 4 weeks 
[17]. We demonstrated that empagliflozin prevented the 
development of NASH in this model by its anti-inflam-
matory and anti-fibrotic effects and the combination of 
empagliflozin and linagliptin improved NASH synergisti-
cally with stronger anti-fibrotic effects.
Methods
Animals and induction of NASH
The novel mouse model of NASH was generated accord-
ing to the protocol of Fujii et  al. [17] In brief, pregnant 
C57BL/6 mice were purchased from CLEA Japan (Tokyo, 
Japan). Neonatal male mice (2  days old) were injected 
subcutaneously with a low dose of streptozotocin (STZ; 
200 μg) and then were fed a high-fat diet (HFD32; CLEA-
Japan, Tokyo, Japan) from 4 weeks after birth. This mouse 
model progresses from NAFLD to NASH by 8 weeks of 
age and develops HCC at 16 weeks [17]. Male littermates 
fed a normal diet (CE-2; CLEA-Japan) without injection 
of STZ were used as a normal control group. All experi-
ments were approved by the animal care and use com-
mittee of Dokkyo Medical University.
Both linagliptin and empagliflozin were provided by 
Boehringer Ingelheim Pharma GmbH Co. (KG, Biberach 
an der Riss, Germany).
NASH mice aged 6  weeks were divided into the fol-
lowing four groups (n =  6 per group): a vehicle group, 
a linagliptin (10 mg/kg) group, an empagliflozin (10 mg/
kg) group, and a linagliptin (10  mg/kg) +  empagliflozin 
(10  mg/kg) group. The dose of empagliflozin at 10  mg/
kg is an effective pharmacological dose used in animal 
experiments [18].
Six male C57/B16 mice of the same age fed a normal 
diet were used as the controls. All animals were provided 
with food and water ad libitum. After grouping, linaglip-
tin and empagliflozin were administered once daily by 
oral gavage for 3 weeks. Then the mice were sacrificed for 
collection of liver tissue samples and blood was obtained 
via cardiac puncture just death. Samples were centri-
fuged and the serum was stored at −80 °C until use. Fast-
ing blood glucose levels (16 h fast) were measured with a 
Glutest Neo Sensor (Sanwa Chemical, Shizuoka, Japan). 
Blood levels of alanine aminotransferase (ALT), triglyc-
erides (TG), free fatty acids (FFA), and glycated albumin 
(GA) were measured with an auto-analyzer (JEOL Ltd., 
Tokyo, Japan). Serum insulin was measured with an 
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enzyme immunoassay (Shibayagi Co., Shibukawa, Japan). 
The TG content of in the liver tissue was measured using 
a Triglyceride E-test kit (Wako, Tokyo, Japan).
Liver tissue samples from the left lobe was embedded 
in tissue Tek O.C.T. compound (Sakura Finetek, Tokyo, 
Japan), snap frozen in liquid nitrogen, and stored at 
−80 °C. Sections (5 μm) were cut, dried in air, and fixed 
in acetone. For hematoxylin and eosin (H–E) staining, 
liver sections prefixed in Bouin’s solution were stained 
with Lillie-Mayer’s hematoxylin (Muto Pure Chemicals, 
Tokyo, Japan). Based on observation of H–E stained sec-
tions, the NAFLD activity score (NAS) was calculated 
from the degree of steatosis, lobular inflammation, and 
hepatocyte ballooning according to the definition of 
Kleiner et al. [19].
To assess development of liver fibrosis, liver sections 
were stained with Sirius red. The positive areas of Sirius 
red staining in five non-overlapping fields were measured 
with DP manager/controller and WIN Roof Ver.5.8.1 
analysis software (Mitani Co., Tokyo, Japan).
Immunohistochemical staining was performed with 
anti-F4/80 antigen antibody (Spring Bioscience, Pleas-
anton, CA, USA), anti-α-smooth muscle actin antibody 
(SMA; Sigma Aldrich, St Louis, MO, USA), and anti-
CD26 antibody (Cell Signaling Technology, Beverly, MA, 
USA). For quantitative analysis of the F4/80-, α-SMA-, 
and CD26-positive areas, bright images of stained liver 
section were captured around the central vein at 200× 
magnification using a digital camera (BX53 Olympus 
Japan, Tokyo, Japan). Then the positive areas in three to 
five non-overlapping fields were measured with DP man-
ager/controller and WIN Roof Ver.5.8.1 analysis software.
Quantitative real‑time RT‑PCR
Total RNA was extracted from liver tissues using an SV 
Total RNA Isolation System (Promega, Madison, WI, 
USA) and was reversed transcribed to obtain cDNA with 
SuperScript III First Strand Synthesis Super mix (Invitro-
gen, Carlsbad, CA, USA). Then real-time quantitative RT-
PCR was performed using FastStart SYBR Green Master 
Mix (Roche Applied Science, Mannheim, Germany) and 
the following probes: type 1 collagen (NM-007742.3), 
type 3 collagen (NM-009930.2), TNF-α (NM-013693.3), 
IL-6 (NM_012589.1), MCP-1 (NM-011333.3), SREBP-
1c (NM-011480.3), ACC1 (NM-133360.2), ACC2 (NM-
133904.2), SCD-1 (NM-009127.4), FAS (NM-134383.2), 
PPAR-α (NM-001113418.1), ACOX-1 (NM-015729.3), 
and CD26 (NM-001159543.1).
The expression of mRNAs for TNF-α, IL-6, MCP-
1, SOCS3, type 1 collagen, type 3 collagen, FAS, 
ACC-1, PPAR-α, and ACOX-1 was calculated as a ratio to 
GAPDH mRNA expression.
Statistical analysis
Data were expressed as the mean ± standard error of the 
mean (SEM). Differences between groups were analyzed 
by the Kruskal–Wallis test with Dunn’s multiple compar-
ison test. A probability (P) value <0.05 was accepted as 
indicating statistical significance.
Results
Effect of empagliflozin and linagliptin on body weight 
and biochemical parameters
On day 21, body weight was moderately lower in the 
diabetic animals than in the control group. As expected, 
plasma glucose was significantly higher in the vehicle 
group than in the control group and was also significantly 
higher in the linagliptin group. Serum glycated albumin 
(GA) was significantly higher in the vehicle group and the 
linagliptin group than in the control group. Serum GA 
was lower in the empagliflozin group in compared with 
the vehicle group or the linagliptin group. Serum ALT 
was significantly lower in the empagliflozin group than 
in the vehicle group. Free fatty acids were elevated in the 
STZ-treated groups compared to the control group. Fast-
ing serum insulin was higher in the linagliptin + empa-
gliflozin group than in the vehicle group (Table 1).
Effect of empagliflozin and linagliptin on the liver/body 
weight ratio and hepatic triglyceride (TG) content
The liver/body weight ratio was higher in the vehicle-
treated group and the linagliptin-treated group than in 
the control group, while it was significantly lower in the 
empagliflozin group and the linagliptin +  empagliflozin 
group than in the vehicle group or the linagliptin group 
(Fig. 1a). The hepatic TG content was higher in the vehi-
cle group than in the control group, while it was lower in 
the linagliptin, empagliflozin, and linagliptin + empagli-
flozin groups compared with the vehicle group (Fig. 1b).
Effect of empagliflozin and linagliptin on the histological 
NAFLD activity score (NAS)
Examination of H–E stained liver sections revealed fatty 
degeneration, inflammatory cell infiltration, and hepa-
tocellular ballooning, predominantly around the central 
veins, in mice from the vehicle group. The NAS score 
was significantly higher in the diabetic animals than in 
the non-diabetic control group (Fig.  2). The NAS score 
was significantly lower in the empagliflozin and linaglip-
tin  +  empagliflozin groups compared with the vehicle 
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group or the linagliptin group. The scores of each compo-
nent of NAS in all groups were shown in Table 2.
Effect of empagliflozin and linagliptin on hepatic 
inflammation
Immunohistochemical staining showed that expres-
sion of F4/80 antigen, a marker of macrophages, was 
increased in the livers of the vehicle-treated mice 
(Fig. 3a). Treatment with linagliptin significantly reduced 
F4/80 antigen expression in the peri-central zone of the 
liver compared with the vehicle group (Fig. 3a). Expres-
sion of F4/80 mRNA was increased in vehicle-treated 
NASH mice compared with control mice, while it was 
significantly decreased in the empagliflozin and linaglip-
tin  +  empagliflozin groups compared with the vehicle 
group (Fig. 3c).
Expression of TNF-α mRNA was increased in vehicle-
treated NASH mice compared with control mice (Fig. 4), 
while it was significantly decreased in the empagliflozin 
and linagliptin  +  empagliflozin groups compared with 
the vehicle group or the linagliptin group. Similarly, 
MCP-1 mRNA expression was significantly decreased in 
the empagliflozin group and the linagliptin + empagliflo-
zin group relative to the vehicle group or the linagliptin 
group (Fig. 4). Expression of SOCS3 mRNA was signifi-
cantly decreased in the empagliflozin group (Fig. 4).
Effect of empagliflozin and linagliptin on hepatic fibrosis
We next investigated whether empagliflozin prevented 
the progression of hepatic fibrosis, which is the advanced 
stage of NASH. First, liver fibrosis was assessed by Sirius 
red staining.
The collagen deposition was significantly lower in 
the linagliptin group, the empagliflozin group, and 
the empagliflon  +  empagliflozin group relative to the 
vehicle group. In addition, treatment with linaglip-
tin + empagliflozin significantly reduced collagen depo-
sition in the peri-central vein zone of the liver compared 
Table 1 Body weight and  biochemical parameters on  day 21 in  NASH mice under  diabetic background (vehicle, lina 
10 mg/Kg, Empa 10 mg/Kg, and Lina+Empa) and their normal littermates
Data are mean ± SE
Lina linagliptin; Empa empagliflozin; GA glycated albumin; ALT alanine aminotransferase
* P < 0.05, † P < 0.01, ‡ P < 0.001 vs. control; § P < 0.05, || P < 0.01, ¶ P < 0.001 vs. vehicle; # P < 0.05, ** P < 0.01, †† P < 0.001 vs. linagliptin alone
Control (n = 6) Vehicle (n = 6) Lina 10 mg/Kg (n = 6) Empa 10 mg/Kg (n = 6) Lina + empa (n = 6)
Body weight (g)
 Day 0 22.6 ± 0.2 20.0 ± 0.9 19.9 ± 0.9 20.3 ± 1.2 20.5 ± 1.0
 Day 21 25.1 ± 0.5 21.9 ± 0.7 21.6 ± 0.9* 21.8 ± 1.2 22.8 ± 0.6
Plasma glucose (mg/dl) 184.5 ± 14.1 470.7 ± 53.7† 479.0 ± 49.2† 319.3 ± 35.1 345.0 ± 57.6
GA (%) 2.35 ± 0.36 5.86 ± 0.73* 5.53 ± 0.43* 2.58 ± 0.50§, # 3.32 ± 0.44
ALT (U/l) 28.3 ± 3.7 42.8 ± 5.7 52.5 ± 15.9 20.7 ± 4.0§ 23.8 ± 2.3
Triglyceride (mg/dl) 40.8 ± 5.3 36.8 ± 7.8 37.3 ± 7.3 26.0 ± 6.3 43.2 ± 8.4
Free fatty acid (mEq/l) 0.76 ± 0.06 1.72 ± 0.15† 1.80 ± 0.29† 2.02 ± 0.21‡ 2.10 ± 0.06‡








































Fig. 1 Liver to body weight ratio (a) and liver triglyceride content (b) in the five groups. Data are mean ± SE. *P < 0.05, †P < 0.01, ‡P < 0.001 vs. 
control; §P < 0.05, ||P < 0.01, ¶P < 0.001 vs. vehicle; #P < 0.05 vs. Linagliptin alone
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with that in the linagliptin or the empagliflozin group 
(Fig. 5).
Immunohistochemical staining showed increased 
hepatic expression of α-SMA, a marker of fibrosis, in 
vehicle-treated NASH mice (Fig.  6a, b). Treatment with 
linagliptin  +  empagliflozin reduced α-SMA expression 
in the peri-central vein zone of the liver compared with 
that in the vehicle group. In addition, expression of both 
type 1 and 3 collagen mRNA was significantly lower in 
the linagliptin + empagliflozin group than in the vehicle 
group (Fig. 6c, d).
Effect of empagliflozin and linagliptin on hepatic fat 
metabolism
We subsequently investigated whether empagliflozin had 
an influence on lipid metabolism in the liver. Expression 
of mRNA for FAS, a gene involved in fatty acid produc-
tion (lipogenesis), was significantly higher in vehicle-
treated NASH mice than in control mice. The expression 
of FAS mRNA was significantly lower in the linaglip-
tin +  empagliflozin group than in the vehicle group or 
the linagliptin group. Similarly, expression of mRNA for 
ACC1, another gene involved in lipogenesis, was sig-
nificantly lower in the linagliptin + empagliflozin group 
than in the vehicle group or the linagliptin group (Fig. 7). 
We found no significant differences in the expression of 
beta oxidation-related genes in the five groups.
On the other hand, the expression of mRNA for 
PPAR-α was significantly decreased in the NASH groups 
compared with the control group irrespective of drug 
treatment. Neither linagliptin nor empagliflozin affected 
the expression of PPAR-α and ACOX1, both genes 
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Fig. 2 Representative microphotographs of liver sections stained with hematoxylin eosin and NAFLD activity score (NAS) in the five groups. Original 
magnification ×200. Data are mean ± SE. ¶P < 0.001 vs. vehicle; **P < 0.01, ††P < 0.001 vs. Linagliptin alone
Table 2 Nonalcoholic fatty liver disease (NAFLD) activity 
score in the five groups
Data are mean ± SD




Control 0 0 0 0
Vehicle 1.3 ± 0.5 2.3 ± 0.5 2 5.7 ± 0.8
Linagliptin  
10 mg/Kg 
0.8 ± 0.4 2.2 ± 0.4 2 5.0 ± 0.6
Empagliflozin  
10 mg/Kg
1 1.3 ± 0.5 1.0 ± 0.6 3.3 ± 0.5
Linagliptin +  
empagliflozin
0.8 ± 0.4 2 1 3.8 ± 0.4
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Effect of empagliflozin and linagliptin on hepatic CD26/
DPP‑4 expression
Since plasma DPP-4 activity is increased in patients with 
NAFLD [20] and patients who have type 2 diabetes with 
elevated liver enzymes [21], treatment with DPP-4 inhibi-
tors may prevent the development of NASH. Therefore, 
we investigated the effects of linagliptin or empagliflozin 
on expression of CD26/DPP-4 in the liver. Immunohisto-
chemical staining showed that CD26/DPP-4 expression 
was unexpectedly higher in the linagliptin group than in 
the vehicle group (data not shown). Hepatic expression 
of CD26 mRNA was significantly lower in the vehicle, 
linagliptin, empagliflozin, and linagliptin + empagliflozin 
groups than in the control group (data not shown).
Discussion
The present study demonstrated for the first time that the 
combination of empagliflozin and linagliptin prevented 
development of NASH in a novel mouse model of NASH 
with diabetes. NAS was significantly prevented in both 
the animals treated with empagliflozin alone and those 
receiving linagliptin + empagliflozin compared with the 
vehicle group or the linagliptin group. Treatment with 
empagliflozin ameliorated hepatic steatosis, inflamma-
tion, and fibrosis in this novel model of NASH and dia-
betes. We obtained histological proof that empagliflozin 
prevents development of NASH in our mouse model 
of NASH and diabetes. Several studies have shown that 
other SGLT2 inhibitors (ipragliflozin and luseogliflozin) 
alleviate hepatic steatosis or steatohepatitis in obese type 
2 diabetic mice or rats [13–16]. However, all other studies 
examined the effects of SGLT2 inhibitors alone on devel-
opment of NASH in a variety of rodent models [13–16]. 
The present study demonstrated for the first time that 
the combination of SGLT2 inhibitor and DPP-4 inhibitor 
can synergistically ameliorate NASH with stronger anti-
fibrotic effects compared with each drug alone in a new 
model of NASH and diabetes, because we found that the 
extent of liver fibrosis evaluated by Sirius red and alpha-
SMA staining was significantly smaller in the combina-
tion of empagliflozin and linagliptin group than in the 
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Fig. 3 Representative microphotographs of immunohistochemical staining for F4/80 in liver sections (a) and percentage in area of positive immu-
nostaining for F4/80 in the five groups (b). Normalized mRNA expression of F4/80 the liver of the five groups (c). Data are mean ± SE. *P < 0.05, 
‡P < 0.001 vs. control; §P < 0.05, ¶P < 0.001 vs. vehicle
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Fig. 4 Gene expression of inflammation in the liver of the five groups. Normalized mRNA expression tumor necrosis factor (TNF) α (a), monocyte 
chemoattractant protein (MCP)-1 (b), interleukin (IL)-6 (c), and suppressor of cytokine signaling (SOC)-3 (d). Data are mean ± SE. *P < 0.05 vs. con-
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Fig. 5 Representative microphotographs of liver sections stained with Sirius red in the liver sections and percentage in area of positive staining for 
Sirius red in the five groups. Data are mean ± SD. §P < 0.05, ¶P < 0.001 vs. vehicle; #P < 0.05 vs. Linagliptin alone; ‡‡P < 0.05 vs. Empagliflozin alone
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Treatments with empagliflozin alone as well as linaglip-
tin alone decreased the hepatic TG content, in agreement 
with the findings of a previous study regarding linaglip-
tin [5]. The TG content of the liver is closely associated 
with steatosis in NASH as well as with de novo lipogen-
esis [22]. Thus, empagliflozin could be a novel therapy for 
both NAFLD and NASH associated with diabetes. The 
mechanisms underlying reduction of the hepatic TG con-
tent by empagliflozin remain to be elucidated. One possi-
ble explanation is that empagliflozin inhibits an increase 
of de novo lipogenesis, since the present study showed 
that expression of both FAS and ACC1, genes involved 
in de novo lipogenesis [23], was significantly lower in 
the linagliptin  +  empagliflozin group than in the vehi-
cle group or the linagliptin group. FAS is a key enzyme 
involve in hepatic fatty acid biosynthesis and is believed 
to be a determinant of the maximal capacity of the liver 
to synthesize fatty acids by de novo lipogenesis, because 
it catalyzes the last step in the fatty acid biosynthetic 
pathway [23]. Thus, improvement of NASH by empagli-
flozin may be associated with a decrease of fatty acid pro-
duction (de novo lipogenesis) rather than an increase of 
fatty acid oxidation. In fact, a very recent study also has 
demonstrated that ipragliflozin improved hepatic steato-
sis in high-fat-induced and leptin-deficient (ob/ob) obese 
irrespective of body weight reduction, and that ipragliflo-
zin reduced the gene expression of de novo lipogenesis, 
while it did not change the expression of β oxidation-
related genes [15].
Inhibition of SGLT2 has been shown to reduce glucose 
reabsorption, which means substantial urinary loss of glu-
cose (calories) in adult patients taking SGLT2 inhibitors 
[8, 10]. Over a certain term, the cumulative loss of calo-
ries may lead to substantial weight loss [8, 10]. A meta-
analysis demonstrated that ≥5  % weight loss improves 
hepatic steatosis and ≥7  % weight loss also improves 
NAS, although fibrosis was unchanged [24]. However, 
we found no significant difference in body weight among 
the five groups after treatment, suggesting that improve-
ment of NASH by empagliflozin may be independent of 
weight reduction. Mechanisms responsible for the lack 
of weight reduction by empagliflozin in our study remain 
to be unclear. A previous study reported that the persis-
tent urinary glucose excretion induced by dapagliflozin 
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Fig. 6 Representative microphotographs of immunohistochemical staining for α-smooth muscle antigen (SMA) in liver sections and percentage 
in area of positive immunostaining for α-SMA in the five groups (a, b). Gene expression of fibrosis in the liver of the five groups. Normalized mRNA 
expression of collagen 1 and 3 (c, d). Data are mean ± SD. *P < 0.05 vs. control; §P < 0.05, ¶P < 0.001 vs. vehicle
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was accompanied by compensatory hyperphagia, which 
attenuated the weight loss induced by SGLT2 inhibition 
[25]. Because all animals were provided with food and 
water ad libitum in our study, it is possible that overeat-
ing induced by empagliflozin was associated with lack of 
effects on weight loss in the empagliflozin group or in the 
combination of empagliflozin and linagliptin group.
Accumulation of fat in the liver can occur due to excess 
dietary intake, increased delivery of fatty acid to the liver, 
inadequate fatty acid oxidation, and increased de novo 
lipogenesis [17]. Hepatic FAS synthesizes lipids (fatty 
acids) that are stored as lipid droplets [26]. Thus, reduc-
tion of hepatic FAS (and ACC1) mRNA levels by empa-
gliflozin may have contributed to the improvement of 
NASH independently of weight reduction in our mouse 
model.
The present study also demonstrated for the first 
time that the combination of empagliflozin and lina-
gliptin reduced the collagen deposition (Sirius red 
staining areas) and the expression of α-SMA protein, 
a marker of activated myofibroblasts (hepatic stellate 
cells) [27], around the central veins, as well as decreas-
ing the expression of type 1 and 3 collagen mRNA. It has 
been suggested that α-SMA may be a valuable marker 
for evaluation of stellate cell activation and progression 
of hepatic fibrosis [27]. If this combination therapy can 
prevent hepatic fibrosis, an advanced stage of NASH, it 
could subsequently stop progression to cirrhosis and 
HCC in NASH patients with diabetes.
The mechanisms contributing to reduction of hepatic 
fibrosis by the combination of empagliflozin and lina-
gliptin remain unclear. One possible explanation for 
the anti-fibrotic effect of this combination therapy is 
that linagliptin prevents the infiltration of macrophages 
(F4/80 positive cells) into lobular lesions, while empagli-
flozin inhibits the hepatic expression of proinflammatory 
cytokines such as IL-6, TNF-α, and MCP-1, which are 
regarded as hallmarks of NASH [28]. Thus, inhibition of 
inflammation in the liver may contribute to inhibition of 
hepatic fibrosis in NASH mice treated with the combina-
tion of empagliflozin and linagliptin.
A number of drugs have the potential to alleviate 
NASH in diverse ways, such as anti-inflammatory and 
antioxidant actions, reduction of de novo lipogenesis, 
and promotion of β-oxidation [29]. Several studies have 
demonstrated that DPP-4 inhibitors can prevent and 
improve liver steatosis in diabetic mice or rodents fed a 
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Fig. 7 Gene expression of lipid metabolism in the liver of the five groups. Normalized mRNA expression of fatty acid synthase (FAS) (a), acetyl-CoA 
carboxylase (ACC) 1 (b), peroxisome proliferator-activated receptor (PPAR) α (c), and acyl-coenzyme A oxidase (ACOX)1 (d). Data are mean ± SD. 
*P < 0.05, †P < 0.01, ‡P < 0.001 vs. control; §P < 0.05, ||P < 0.01, ¶P < 0.001 vs. vehicle; #P < 0.05, **P < 0.01, ††P < 0.001 vs. Linagliptin alone
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alleviates hepatic steatosis and inflammation by reducing 
macrophages infiltration and lobular inflammation, as 
well as expression of TNF-α and IL-6 [30]. The improve-
ment of hepatic steatosis by linagliptin was also accom-
panied by a decrease in expression of fatty acid synthase 
[5, 30]. In the present study, we failed to find a signifi-
cant reduction of NAS in the linagliptin group. Both the 
empagliflozin and linagliptin  +  empagliflozin groups 
showed significant improvements of NAS and reduction 
of gene expression of proinflammatory cytokines in the 
liver compared with the vehicle or linagliptin groups, 
suggesting that empagliflozin may have a stronger effect 
on NASH than linagliptin in this model.
We found that empagliflozin significantly decreased 
the expression of SOCS3 mRNA in the livers of NASH 
mice compared with vehicle-treated NASH mice. Expres-
sion of IL-6 mRNA was also significantly decreased in the 
empagliflozin group and the linagliptin  +  empagliflozin 
group relative to that in the vehicle group. IL-6 blocks the 
insulin-signaling pathway, partly by inducing SOCS3 in 
hepatocytes [31]. SOCS3 inhibits the action of insulin by 
biding to the insulin receptor or IRS-1 and-2, followed by 
their ubiquitination and degradation [32]. Although it was 
reported that linagliptin inhibits hepatic SOCS3 expres-
sion in NAFLD and NASH mice [5, 30], we failed to find 
a significant reduction of SOCS3 mRNA expression in the 
liver after treatment with linagliptin. Thus, empagliflozin 
may have the potential to ameliorate insulin resistance in 
the liver due to inhibition of the IL-6-SOCS3 axis.
The present study had some limitations. Because of a 
significant difference in plasma glucose level after treat-
ment between empagliflozin and linagliptin, the pos-
sibility that empagliflozin may prevent development of 
NASH partly due to its glucose-lowering effects could 
be not excluded in this study. Another limitation is that 
this model lacks obesity and insulin resistance, which are 
associated with NASH in humans.
In conclusion, we demonstrated that empagliflozin, 
an SGLT2 inhibitor, has the potential to prevent NASH 
through its anti-steatotic and anti-inflammatory actions 
in a mouse model of NASH with diabetes. In addition, 
the combination of empagliflozin and linagliptin syn-
ergistically prevented development of liver fibrosis in 
this model. Thus, empagliflozin prevented development 
of the pathological features of NASH, suggesting that 
it could become a simple new therapeutic strategy for 
NASH associated with diabetes.
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